- Home
- CVRX vs LYEL Comparison
CVRX vs LYEL Comparison
Compare CVRX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVRX
- LYEL
- Stock Information
- Founded
- CVRX 2000
- LYEL 2018
- Country
- CVRX United States
- LYEL United States
- Employees
- CVRX N/A
- LYEL N/A
- Industry
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- CVRX Health Care
- LYEL Health Care
- Exchange
- CVRX Nasdaq
- LYEL Nasdaq
- Market Cap
- CVRX 174.4M
- LYEL 207.7M
- IPO Year
- CVRX 2021
- LYEL 2021
- Fundamental
- Price
- CVRX $5.89
- LYEL $8.69
- Analyst Decision
- CVRX Buy
- LYEL Sell
- Analyst Count
- CVRX 7
- LYEL 2
- Target Price
- CVRX $14.50
- LYEL $20.00
- AVG Volume (30 Days)
- CVRX 232.7K
- LYEL 249.1K
- Earning Date
- CVRX 07-28-2025
- LYEL 08-06-2025
- Dividend Yield
- CVRX N/A
- LYEL N/A
- EPS Growth
- CVRX N/A
- LYEL N/A
- EPS
- CVRX N/A
- LYEL N/A
- Revenue
- CVRX $52,870,000.00
- LYEL $65,000.00
- Revenue This Year
- CVRX $11.53
- LYEL N/A
- Revenue Next Year
- CVRX $18.61
- LYEL N/A
- P/E Ratio
- CVRX N/A
- LYEL N/A
- Revenue Growth
- CVRX 25.62
- LYEL N/A
- 52 Week Low
- CVRX $4.30
- LYEL $7.65
- 52 Week High
- CVRX $18.55
- LYEL $45.42
- Technical
- Relative Strength Index (RSI)
- CVRX 41.15
- LYEL 44.96
- Support Level
- CVRX $5.54
- LYEL $8.96
- Resistance Level
- CVRX $5.96
- LYEL $10.96
- Average True Range (ATR)
- CVRX 0.40
- LYEL 2.14
- MACD
- CVRX -0.03
- LYEL -0.17
- Stochastic Oscillator
- CVRX 21.99
- LYEL 16.91
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.